RATIONALE-315: Neoadjuvant Tislelizumab + Chemo in Resectable NSCLC – ESMO 2024 Results

1 Views
Published
Dive into the latest data from the RATIONALE-315 trial presented at ESMO 2024, evaluating event-free survival (EFS) and overall survival (OS) with neoadjuvant tislelizumab plus chemotherapy followed by adjuvant tislelizumab in patients with resectable non-small cell lung cancer (NSCLC).

???? Stay updated with cutting-edge immunotherapy research in thoracic oncology.


#RATIONALE315 #ESMO2024 #NSCLC #Tislelizumab #LungCancer #Immunotherapy #CancerTrials
Category
Oncology
Be the first to comment